EMPAGLIFLOZIN; LINAGLIPTIN (empagliflozin; linagliptin) by Annora Pharma is contains: empagliflozin, a sglt2 inhibitor, linagliptin, a dpp-4 inhibitor, and metformin hcl, a biguanide. Approved for cardiovascular (cv) death in adults with type 2 diabetes mellitus, established cv disease [see ], established cv disease and 2 more indications.
Drug data last refreshed 14h ago
contains: empagliflozin, a SGLT2 inhibitor, linagliptin, a DPP-4 inhibitor, and metformin HCl, a biguanide. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting…
Worked on EMPAGLIFLOZIN; LINAGLIPTIN at Annora Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.